US Senate launches hearings into soaring prices of off-patent drugsBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6733 (Published 11 December 2015) Cite this as: BMJ 2015;351:h6733
- Michael McCarthy
The US government may need to act to discourage drug companies from hiking the prices of off-patent drugs, senators from both main parties said at the first of a series of hearings on soaring drug prices held by the Senate Special Committee on Aging on 9 December.
The hearings were prompted by recent reports of drug companies increasing prices by as much as 40-fold for off-patent drugs for which there was no current competition from generic versions. In one case the New York City based Turing Pharmaceuticals acquired pyrimethamine (Daraprim), an antiparasitic drug used in the United …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial